A novel selective decoy oligodeoxynucleotide (dODN)-doxorubicin (DOX) complex is reported for cancer theranostics. It eliminates the use of a ligand or carrier for targeted delivery and disassembles into therapeutic dODN and DOX upon encountering over-activated STAT3 in cancer cells. Hence, in situ STAT3 probing and synergistic anti-cancer effect are attained at the same time.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/c5cc04435a | DOI Listing |
Publication Analysis
Top Keywords
stat3 probing
8
probing synergistic
8
synergistic anti-cancer
8
selective decoy-doxorubicin
4
decoy-doxorubicin complex
4
complex targeted
4
targeted co-delivery
4
co-delivery stat3
4
anti-cancer novel
4
novel selective
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!